AKTS
Aktis Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$21.88
−4.29%Margins
Gross margin
84.8%
EBITDA margin
-772.8%
EBIT margin
-866.6%
Net margin
-727.0%
FCF margin
-840.6%
-15.1%
Return on equity
-13.1%
Return on assets
-17.6%
Return on invested capital
0.02x
Asset turnover
-$75.3M
Cash from operations
$9.30
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026